<DOC>
	<DOC>NCT03011177</DOC>
	<brief_summary>To assess the efficacy and safety of Teneligliptin and Linagliptin in the type 2 DM patients.</brief_summary>
	<brief_title>Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Patients who are 19 years or older on screening Patients with type 2 diabetes mellitus Patients with 7.0% ≤ HbA1c ≤ 11.0% at the screening visit Patients with FPG &lt;15mmol/L(270mg/dL) on screening</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>